Registration Dossier

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: GLP-compliant guideline study, available as unpublished report, no restrictions, fully adequate for assessment. Test itm purity less than 80%.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2003
Report date:
2003

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
Qualifier:
according to guideline
Guideline:
EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
Version / remarks:
96/54/EC
Qualifier:
according to guideline
Guideline:
EPA OPPTS 870.1100 (Acute Oral Toxicity)
GLP compliance:
yes (incl. QA statement)
Remarks:
Experimental Toxicology and Ecology, BASF Aktiengesellschaft, 67056 Ludwigshafen/Rhein, Germany
Test type:
acute toxic class method
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
4-({[4-(acryloyloxy)butoxy]carbonyl}oxy)benzoic acid
EC Number:
608-403-9
Cas Number:
297132-04-8
Molecular formula:
C15H16O7
IUPAC Name:
4-({[4-(acryloyloxy)butoxy]carbonyl}oxy)benzoic acid
Details on test material:
- Name of test material (as cited in study report): 4-(4-Acryloyloxy-butoxycarbonyloxy)-benzoic acid
- Physical state / appearance: Solid / white
- Degree of purity / content: 66.7 area %

- Date of production: December 01, 2002
- Homogeneity: The test substance was homogeneous by visual inspection.
- Storage conditions: Room temperature, protected from humidity and Iight

Test animals

Species:
rat
Strain:
Wistar
Sex:
female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Charles River Deutschland GmbH, Sandhofer Weg 7, 97633 Sulzfeld
- Age at study initiation: approx. 14 - 18 weeks
- Weight at study initiation: Animals of comparable weight (202-217 g)
- Fasting period before study: 16 hours
- Housing: Single housing in stainless steel wire mesh cages, type DK-III (Becker & Co., Castrop-Rauxel, FRG)
- Diet: Kliba-Labordiät (Maus / Ratte Haltung ("GLP"), Provimi Kliba SA, Kaiseraugst, Basel, Switzerland, ad libitum
- Water: Tap water ad libitum
- Acclimation period: at least 5 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Air changes (per hr): fully air-conditioned rooms.
- Photoperiod (hrs dark / hrs light): 12 / 12

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
CMC (carboxymethyl cellulose)
Remarks:
0.5% CMC-solution
Details on oral exposure:
VEHICLE
- Justification for choice of vehicle: Aqueous formulation corresponds to the physiological medium.

MAXIMUM DOSE VOLUME APPLIED:
- Concentration: 20g/100 mL,
- Administration volume: 10mL/kg
Doses:
2000 mg/kg (containing 1320 mg/kg bw of main component)
No. of animals per sex per dose:
6
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of weighing: Individual body weights shortly before administration (day 0), weekly thereafter and at the end of the study.
- Frequency of observations: Recording of signs and symptoms several times on the day of administration, at least once each workday for the individual animals.
- Mortality: A check for any dead or moribund animal was made twice each workday and once on Saturdays, Sundays and on public holidays.
- Pathology: Necropsy with gross-pathology examination on the last day of the observation period after killing with CO2.

Results and discussion

Effect levels
Sex:
female
Dose descriptor:
LD0
Effect level:
> 1 320 mg/kg bw
Based on:
test mat.
Remarks on result:
other: adjusted for content of main component.
Mortality:
No mortality occurred.
Clinical signs:
- Clinical observation in the second 2000 mg/kg administration group revealed impaired general state, dyspnoea and piloerection and were observed from hour 1 until including hour 5 after administration.
- No clinical observations were observed during clinical examination in the first 2000 mg/kg administration group.
Body weight:
The mean body weights of the administration groups increased throughout the study period.
Gross pathology:
No macroscopic pathologic abnormalities were noted in the animals examined at termination of the study.

Applicant's summary and conclusion

Interpretation of results:
relatively harmless
Remarks:
Migrated information Criteria used for interpretation of results: EU

Categories Display